A case series of PD-1 inhibitor-associated paraneoplastic neurologic syndromes.

Autor: Gill A; Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, United States of America. Electronic address: alexander.gill2@uphs.upenn.edu., Perez MA; Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, United States of America., Perrone CM; Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, United States of America., Bae CJ; Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, United States of America., Pruitt AA; Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, United States of America., Lancaster E; Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, United States of America.
Jazyk: angličtina
Zdroj: Journal of neuroimmunology [J Neuroimmunol] 2019 Sep 15; Vol. 334, pp. 576980. Date of Electronic Publication: 2019 Jun 05.
DOI: 10.1016/j.jneuroim.2019.576980
Abstrakt: Immune checkpoint inhibitors (ICIs) are highly efficacious for treating many solid tumor types. Because of their immune-activating mechanism of action, ICIs can trigger various immune-mediated toxicities. We present three cases: i) a woman with anti-Ri brainstem encephalitis; ii) a man with anti-Hu sensory neuronopathy; and iii) a woman with suspected combined anti-Hu and anti-NMDA paraneoplastic syndromes associated with the initiation of the ICIs pembrolizumab and nivolumab. These cases suggest that ICIs can induce both humoral and cell-mediated paraneoplastic neurologic syndromes. Identifying biomarkers that predict risk of developing ICI-associated paraneoplastic syndromes and the development of efficacious treatment strategies for neurologic ICI-toxicities are critical unmet needs.
(Copyright © 2019 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: